Neil Solomons

3.7k total citations · 3 hit papers
23 papers, 2.1k citations indexed

About

Neil Solomons is a scholar working on Rheumatology, Hepatology and Nephrology. According to data from OpenAlex, Neil Solomons has authored 23 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Rheumatology, 14 papers in Hepatology and 8 papers in Nephrology. Recurrent topics in Neil Solomons's work include Systemic Lupus Erythematosus Research (20 papers), Liver Diseases and Immunity (11 papers) and Renal Diseases and Glomerulopathies (8 papers). Neil Solomons is often cited by papers focused on Systemic Lupus Erythematosus Research (20 papers), Liver Diseases and Immunity (11 papers) and Renal Diseases and Glomerulopathies (8 papers). Neil Solomons collaborates with scholars based in United States, United Kingdom and Netherlands. Neil Solomons's co-authors include Ellen M. Ginzler, Gerald B. Appel, David Jayne, David Wofsy, Mary Anne Dooley, David Isenberg, Gabriel Contreras, Laura Lisk, Eduardo Mysler and LI Leishi and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Kidney International.

In The Last Decade

Neil Solomons

19 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis

2009 734 citations Gerald B. Appel, Gabriel Contreras et al. Journal of the American Society of Nephrology profile →
Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis

2011 421 citations Mary Anne Dooley, David Jayne et al. New England Journal of Medicine profile →
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

2021 299 citations Brad H. Rovin, Y K Onno Teng et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Neil Solomons United States	11	1.9k	1.1k	646	610	373	23	2.1k
Chi Hung To China	24	1.5k 0.8×	330 0.3×	747 1.2×	234 0.4×	236 0.6×	45	2.0k
Beulah Ji United States	14	1.3k 0.7×	311 0.3×	880 1.4×	210 0.3×	619 1.7×	31	1.6k
Paz Lavilla Spain	7	1.9k 1.0×	311 0.3×	1.0k 1.6×	175 0.3×	433 1.2×	8	2.1k
Paula Alba Argentina	9	1.2k 0.7×	245 0.2×	672 1.0×	134 0.2×	273 0.7×	34	1.4k
Dana Tegzová Czechia	15	1.7k 0.9×	166 0.2×	1.0k 1.6×	123 0.2×	657 1.8×	22	2.1k
Juanita Romero‐Díaz Mexico	17	1.0k 0.5×	199 0.2×	639 1.0×	109 0.2×	272 0.7×	50	1.3k
Massimo Radin Italy	21	941 0.5×	271 0.3×	327 0.5×	84 0.1×	133 0.4×	112	1.3k
Cecile Grootscholten Netherlands	21	563 0.3×	289 0.3×	362 0.6×	154 0.3×	153 0.4×	52	1.4k
Juan Carlos Mejía United States	10	909 0.5×	173 0.2×	514 0.8×	114 0.2×	189 0.5×	27	1.3k
Renato Guzmán United States	5	1.4k 0.7×	174 0.2×	1.1k 1.7×	90 0.1×	767 2.1×	10	1.8k

Countries citing papers authored by Neil Solomons

Since Specialization

Citations

This map shows the geographic impact of Neil Solomons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil Solomons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil Solomons more than expected).

Fields of papers citing papers by Neil Solomons

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil Solomons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil Solomons. The network helps show where Neil Solomons may publish in the future.

Co-authorship network of co-authors of Neil Solomons

This figure shows the co-authorship network connecting the top 25 collaborators of Neil Solomons. A scholar is included among the top collaborators of Neil Solomons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil Solomons. Neil Solomons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rovin, Brad H., Clarissa A. Cassol, Samir V. Parikh, et al.. (2025). Effect of Long‐Term Voclosporin Treatment on Renal Histology in Patients With Active Lupus Nephritis With Repeat Renal Biopsies. Arthritis & Rheumatology. 77(10). 1387–1393.

Dall’Era, Maria, Kenneth Kalunian, Neil Solomons, et al.. (2024). Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and ALMS. Lupus Science & Medicine. 11(2). e001319–e001319. 1 indexed citations

McDonald, Stephen, Li Su, Caroline Gordon, et al.. (2022). Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial. Lupus Science & Medicine. 9(1). e000584–e000584. 8 indexed citations

Dall’Era, Maria, Kenneth Kalunian, Michael Eaddy, et al.. (2022). Real-world treatment utilization and economic implications of lupus nephritis disease activity in the United States. Journal of Managed Care & Specialty Pharmacy. 29(1). 36–45. 5 indexed citations

Rovin, Brad H., Y K Onno Teng, Ellen M. Ginzler, et al.. (2021). Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet. 397(10289). 2070–2080. 299 indexed citations breakdown →

Gelder, Teun van, Robert B. Huizinga, Laura Lisk, & Neil Solomons. (2021). Voclosporin: a novel calcineurin inhibitor with no impact on mycophenolic acid levels in patients with SLE. Nephrology Dialysis Transplantation. 37(5). 917–922. 21 indexed citations

Almaani, Salem, Udayan Bhatt, Cristina Arriens, et al.. (2020). Creatinine Fluctuation in Patients With Lupus Nephritis: Considerations for Clinical Trial Endpoints. Kidney International Reports. 5(8). 1302–1305.

Rovin, Brad H., Samir V. Parikh, Robert B. Huizinga, Neil Solomons, & Simrat Randhawa. (2020). Management of Lupus Nephritis (LN) with Voclosporin: An Update from a Pooled Analysis of 534 Patients. Journal of the American Society of Nephrology. 31(10S). 594–594. 4 indexed citations

Caster, Dawn J., Neil Solomons, Simrat Randhawa, & Robert B. Huizinga. (2020). MO019AURORA PHASE 3 TRIAL DEMONSTRATES VOCLOSPORIN STATISTICAL SUPERIORITY OVER STANDARD OF CARE IN LUPUS NEPHRITIS (LN). Nephrology Dialysis Transplantation. 35(Supplement_3). 2 indexed citations

10.

Gelder, Teun van, et al.. (2020). Use of Therapeutic Drug Monitoring Does Not Add Clinical Value for Voclosporin in Patients with Lupus Nephritis. Journal of the American Society of Nephrology. 31(10S). 594–594. 8 indexed citations

11.

Huizinga, Robert B., Neil Solomons, & Mark D. Abel. (2016). SP671CALCINEURIN INHIBITION WITHOUT THERAPEUTIC DRUG MONITORING?. Nephrology Dialysis Transplantation. 31(suppl_1). i318–i319. 1 indexed citations

12.

Solomons, Neil, Abdul Halim Abdul Gafor, Rosnawati Yahya, Tak Mao Chan, & Robert B. Huizinga. (2016). MP130AURION STUDY: MULTI-TARGET THERAPY WITH VOCLOSPORIN, MMF AND STEROIDS FOR LUPUS NEPHRITIS. Nephrology Dialysis Transplantation. 31(suppl_1). i385–i385.

13.

Dall’Era, Maria, Victoria Levesque, Neil Solomons, Matt Truman, & David Wofsy. (2015). Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Lupus Science & Medicine. 2(1). e000089–e000089. 39 indexed citations

14.

Walsh, Michael, Neil Solomons, Laura Lisk, & David Jayne. (2013). Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis With Poor Kidney Function: A Subgroup Analysis of the Aspreva Lupus Management Study. American Journal of Kidney Diseases. 61(5). 710–715. 48 indexed citations

15.

Rovin, Brad H., Samir V. Parikh, Lee A. Hebert, et al.. (2012). Lupus Nephritis. Clinical Journal of the American Society of Nephrology. 8(1). 147–153. 37 indexed citations

16.

Dooley, Mary Anne, David Jayne, Ellen M. Ginzler, et al.. (2011). Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis. New England Journal of Medicine. 365(20). 1886–1895. 421 indexed citations breakdown →

17.

Beissert, Stefan, et al.. (2010). Treating Pemphigus Vulgaris with Prednisone and Mycophenolate Mofetil: A Multicenter, Randomized, Placebo-Controlled Trial. Journal of Investigative Dermatology. 130(8). 2041–2048. 106 indexed citations

18.

Isenberg, David, Gerald B. Appel, Gabriel Contreras, et al.. (2009). Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Lara D. Veeken. 49(1). 128–140. 233 indexed citations

19.

Appel, Gerald B., Gabriel Contreras, Mary Anne Dooley, et al.. (2009). Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis. Journal of the American Society of Nephrology. 20(5). 1103–1112. 734 indexed citations breakdown →

20.

Radhakrishnan, Jai, Dimitrios-Anestis Moutzouris, Ellen M. Ginzler, et al.. (2009). Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney International. 77(2). 152–160. 128 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact